catalyst
biosciences
present
stifel
virtual
healthcare
conference
south
san
francisco
globe
newswire
catalyst
biosciences
nasdaq
cbio
today
announced
nassim
usman
president
chief
executive
officer
clinton
musil
chief
financial
officer
catalyst
biosciences
present
stifel
virtual
healthcare
conference
taking
place
november
details
company
presentation
follows
date
november
time
et
webcast
https
webcast
cbio
archived
webcast
presentation
available
days
events
presentations
section
company
website
catalyst
biosciences
catalyst
research
clinical
development
biopharmaceutical
company
focused
addressing
unmet
medical
needs
rare
hematologic
disorders
protease
engineering
platform
generated
two
clinical
programs
hemophilia
research
program
engineering
subcutaneous
sq
complement
inhibitors
discovery
stage
factor
ix
gene
therapy
construct
cb
hemophilia
b
partnered
preclinical
development
program
biogen
dry
macular
degeneration
amd
product
candidates
generated
protease
engineering
platform
improved
functionality
potency
allow
sq
administration
recombinant
coagulation
factors
complement
inhibitors
high
activity
gene
therapy
constructs
less
frequently
dosed
intravitreal
therapeutics
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
include
statements
product
candidates
generated
catalyst
protease
engineering
platform
improved
functionality
potency
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
including
limited
risk
trials
studies
may
delayed
result
factors
trials
may
satisfactory
outcomes
additional
human
trials
replicate
results
earlier
trials
potential
adverse
effects
may
arise
testing
use
marzaa
including
generation
neutralizing
antibodies
risk
costs
required
develop
manufacture
company
products
higher
anticipated
including
result
delays
development
manufacturing
resulting
factors
risk
biogen
terminate
catalyst
agreement
competition
risks
described
risk
factors
section
company
quarterly
report
filed
securities
exchange
commission
august
filings
securities
exchange
commission
company
assume
obligation
update
statements
except
required
law
contact
ana
kapor
catalyst
biosciences
investors
